Is Amgen Stock a Buy?
(NASDAQ: AMGN) is doing something unusual in 2025. The biotech giant's shares are up 7.2% for the year as I write this while most large-cap healthcare stocks struggle; yet it trades at just 13 times forward earnings estimates compared to 21 for the S 500. That disconnect between performance and valuation creates an opportunity.
With 14 drugs posting double-digit sales growth in the most recent quarter, a promising obesity drug in late-stage trials, and a 3.5% dividend yield, Amgen offers investors a rare combination of growth, income, and value. Here's why this $150 billion pharmaceutical powerhouse deserves a closer look by investors of all stripes.
Image source: Getty Images.
Source Fool.com
Amgen Inc. Aktie
276,40 €
-1,81 %
Die Community sieht Amgen Inc. positiv: Viel mehr Buy- als Sell-Einschätzungen.
Ein positives, aber moderates Potenzial für Amgen Inc. mit einem Kursziel von 292 € im Vergleich zu 276.4 €.
